AnaptysBio Chairman James Topper resigns; John Orwin named Chairman

ANAPTYSBIO, INC

James Topper resigned as Class II director and Chairman effective Sept 15, 2023; no disagreement with company.
Topper will serve as advisor to the Board through Q1 2024 under an Advisory Agreement.
John Orwin appointed Class II director and Chairman on Sept 15, 2023.
Orwin received initial equity grants: option for 3,311 shares (vesting monthly to Jan 2024) and 2,035 RSUs (vest at 2024 annual meeting).
Orwin also granted option for 10,600 shares (3-year monthly vest) and 3,900 RSUs (3-year annual vest).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Orwin

Chairman

ANAB · ANAPTYSBIO, INC

Effective: 2023-09-15
Filed: September 18, 2023, 7:59 PM ET

On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.

Departed

James N. Topper

Chairman

ANAB · ANAPTYSBIO, INC

Effective: 2023-09-15
Successor: John Orwin
Filed: September 18, 2023, 7:59 PM ET

On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John Orwin was appointed as Chairman at ANAPTYSBIO, INC.

Action: appointed
Role: Chairman

Exact text from the filing

On September 15, 2023, the Board appointed John Orwin as a Class II director, a member of the Nominating and Corporate Governance Committee and Chairman of the Board, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

James N. Topper resigned as Chairman at ANAPTYSBIO, INC.

Action: resigned
Role: Chairman

Exact text from the filing

On September 14, 2023, James N. Topper, M.D., Ph.D., advised the Board of Directors (the “ Board ”) of AnaptysBio, Inc. (the “ Company ”) that he would resign as a Class II director and as Chairman of the Board, effective on September 15, 2023.

View on SEC.gov

ANAPTYSBIO, INC filing history →

Source: SEC EDGAR

accession 0001370053-23-000052

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.